<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69525">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02200718</url>
  </required_header>
  <id_info>
    <org_study_id>IR902-007</org_study_id>
    <nct_id>NCT02200718</nct_id>
  </id_info>
  <brief_title>A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis</brief_title>
  <official_title>A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immune Response BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Immune Response BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple
      Sclerosis to demonstrate safety &amp; efficacy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-Center Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for
      Pediatric Multiple Sclerosis to demonstrate safety &amp; efficacy 12 subjects with pediatric MS
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary clinical endpoints are comparisons of MRI &amp; WBC measurements between the treatment groups</measure>
    <time_frame>26 Weeks</time_frame>
    <description>The primary objective is to compare between treatment groups the cumulative number of new gadolinium enhancing (Gd+) lesions on brain MRI &amp; to compare the increases of WBC white blood cell counts in subjects in the treatment groups with Pediatric MS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A Secondary clinical endpoint is the measurement of FOXP3+ expression</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Secondary measurements objectives to compare immunologic evaluations increases in FOXP3+ expression between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Secondary clinical endpoint is the measurment of EDSS scores</measure>
    <time_frame>26 Weeks</time_frame>
    <description>To compare between treatment groups the Measures of neurologic disability EDSS scores utilizing the Kurtzke scale, Patients will be assessed using the EDSS, a 25-foot timed walk, and a nine-hole peg test assessments at weeks 0, 4, 8, 12, 16, 20 &amp; 26 visit then exit the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Secondary clinical endpoint is the measurement of clinical relapses</measure>
    <time_frame>26 Weeks</time_frame>
    <description>To compare the Analysis of clinical relapses between the treatment groups of Pediatric MS subjects at week 26</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>NeuroVax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA V Beta Peptides BV5S2, BV6S5 and BV13S1 emulsified in incomplete Freund's adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFA Incomplete Freund's Adjuvant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil a surfactant system designed to make a water-in-oil emulsion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeuroVax</intervention_name>
    <description>NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1</description>
    <arm_group_label>NeuroVax</arm_group_label>
    <other_name>IR902 TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IFA Incomplete Freund's Adjuvant</intervention_name>
    <description>IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion</description>
    <arm_group_label>IFA Incomplete Freund's Adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages Eligible for Study: 5 Years to 17 Years

          -  Genders Eligible for Study: Both

          -  Accepts Healthy Volunteers: No Criteria

          -  Subject is between 5 and 17 years of age, inclusive

          -  Clinically diagnosed Pediatric MS

          -  Definite Pediatric MS by the revised McDonald criteria (2005) (Appendix A), with a
             pediatric MS course

          -  Expanded Disability Status Scale (EDSS) &lt;= score 6.5 (Appendix B) Two or more
             documented clinical relapses of MS in the preceding 24 months OR one documented
             clinical relapse of MS in the preceding 12 months prior to screening

          -  Laboratory values within the following limits:

               -  Creatinine 1 . 5 x high normal

               -  Hemoglobin

        Exclusion Criteria:

          -  Subjects currently prescribed Campath or Lemtrada
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Bourdette, FAAN MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard M Bartholomew, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Immune Response BioPharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard M Bartholomew, Ph.D</last_name>
    <phone>1-858-414-4664</phone>
    <email>Richardmbartholomew@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple Sclerosis Center Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard M Bartholomew, PhD</last_name>
      <phone>858-414-4664</phone>
      <email>Richardmbartholomew@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dennis Bourdette, MD F.A.A.N.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.immuneresponse.net</url>
    <description>Immune Response BioPharma, Inc.</description>
  </link>
  <link>
    <url>http://ohsu.edu</url>
    <description>OHSU</description>
  </link>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 22, 2016</lastchanged_date>
  <firstreceived_date>July 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis Pediatric MS NeuroVax Vaccine Therapeutic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
